BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug’s label.
Lawmakers signal willingness to counter China’s biotech gains
Lawmakers on a bipartisan House panel conveyed they are ready to tackle China’s growing dominance in the development of new medicines and the ingredients that


